Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

This publication has 57 references indexed in Scilit:

• The effect of metformin and thiazolidinedione use on lung cancer in diabetics
  BMC Cancer, 2012
• Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
  Diabetologia, 2012
• Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis
  Canadian Medical Association Journal, 2012
• Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
  Diabetologia, 2012
• Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
  Diabetes Care, 2012
• Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
  Hepatology, 2011
• Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
  Diabetes Care, 2011
• Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes
  Kidney International, 2009
• Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
  Canadian Medical Association Journal, 2009
• Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease
  Journal of the American Society of Nephrology, 2008